Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Ongoing Trials of Belantamab Mafodotin in MM and Optimal Position in Treatment Landscape

February 18th 2022

Joshua Richter, MD, and Sagar Lonial, MD, FACP, review key ongoing clinical trials with belantamab mafodotin in patients with multiple myeloma and the optimal position for belantamab mafodotin in the myeloma treatment landscape.

Managing AEs With Belantamab Mafodotin in Relapsed/Refractory Myeloma

February 18th 2022

Katja Weisel, MD, shares recommended strategies for the prevention and management of potential ocular effects of belantamab mafodotin in multiple myeloma.

Frontline Treatment Options for Marginal Zone Lymphoma

February 18th 2022

Shared insight on frontline treatment approaches for patients diagnosed with marginal zone lymphoma.

Clinical Pearls in the Management of Follicular Lymphoma

February 18th 2022

Clinical pearls for community physicians regarding the optimal management of patients with follicular lymphoma.

Monoclonal Antibodies for Treatment of R/R DLBCL

February 17th 2022

Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.

Real-World Data With CAR-T Therapies in R/R DLBCL

February 17th 2022

Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.

Challenges With Diagnosis of ITP

February 16th 2022

Experts discuss lack of consensus in diagnosis of ITP and challenges physicians face.

ITP Treatment in Pregnancy

February 16th 2022

ITP experts share considerations in the treatment of pregnant patients with ITP.

Gerds Takes a Closer Look at Treatment Sequencing in Hematologic Malignancies

February 16th 2022

Aaron T. Gerds, MD, MS, discusses the use of TKIs, targeted agents, JAK inhibitors, and cellular therapy in hematologic malignancies.

An Overview of CML Treatment Toxicities

February 16th 2022

An overview of the general toxicities patients may experience while undergoing therapy for chronic myeloid leukemia.

Chronic Myeloid Leukemia: Asciminib’s Toxicity Profile

February 16th 2022

A brief review of asciminib’s toxicity profile and how to best manage adverse events in patients with chronic myeloid leukemia.

Dr. Wang on the Evolution of Ibrutinib in the Treatment Landscape of MCL

February 14th 2022

Michael Wang, MD, discusses the evolution of ibrutinib in the treatment landscape of mantle cell lymphoma.

ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

February 14th 2022

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.

Updates From ASH 2021 for Belantamab-based Combinations in Myeloma

February 11th 2022

Ola Landgren, MD, PhD, and Joshua Richter, MD, review belantamab mafodotin–based combination regimens currently being evaluated in relapsed/refractory multiple myeloma, as well as the newly diagnosed setting, as presented at the recent ASH 2021 meeting.

Optimizing the Sequencing of Therapy in Follicular Lymphoma

February 11th 2022

Panelists use an illustrative clinical case to comprehensively discuss the selection and sequencing of therapies for patients with follicular lymphoma.

PI3K Inhibitors in Relapsed/Refractory Follicular Lymphoma

February 11th 2022

A review of the role of PI3K inhibitors in the treatment of follicular lymphoma, and how they have been used to improve patient outcomes.

Cleveland Clinic Faculty Speak to Shifting Standards in Hematologic Malignancies

February 10th 2022

We had the pleasure of speaking with faculty from an OncLive® Institutional Perspectives in Cancer webinar on hematologic malignancies, hosted in partnership with Cleveland Clinic, to discuss current practice patterns and emerging therapies in chronic myeloid leukemia, chronic lymphocytic leukemia, myelofibrosis, and acute lymphoblastic leukemia.

Dr. Evens on the Design of a Retrospective Analysis Evaluating Salvage Regimens in R/R Hodgkin Lymphoma

February 10th 2022

Andrew M. Evens, DO, MSc, discusses the design of a retrospective analysis evaluating in relapsed/refractory classic Hodgkin lymphoma.

Safety With CAR-T Therapies in R/R DLBCL

February 10th 2022

Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.

CAR-T Therapies in R/R DLBCL

February 10th 2022

Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.